
|Videos|January 31, 2021
Glaukos COO shares product updates, 2021 pipeline
Author(s)David Hutton, Alex Delaney-Gesing
Glaukos Corporation's COO Chris Calcaterra gives an update on the company's latest 24-month phase 2b data for its iDose TR sustained-release travoprost implant, next steps for securing FDA approval, and his outlook for 2021.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
EYDENZELT, Celltrion’s biosimilar referencing EYLEA, approved by FDA
2
Quantifying intermittent retinal capillary perfusion in RVO and PDR
3
Q&A: Inder Paul Singh, MD, explores technician empowerment via the Academy Technician Training Platform
4
AAO 2025: Technician training platform expands education opportunities in ophthalmology
5